How can the gene therapy industry drive down the cost of goods to better serve patients?

Tuesday June 13th 2023 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

How can the gene therapy industry drive down the cost of goods to better serve patients?

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

The cost per dose of viral vector therapeutics is a major challenge for the widespread accessibility of gene therapy products, driven by a high cost of goods and manufacturing expenses.

In this webinar, we will identify the components that contribute to these high costs and pinpoint the biggest challenges the industry must overcome to reduce the cost per dose. We will discuss how tools such as process intensification (PI) and cost modeling can help us understand the main cost drivers and the impact process optimization can have on the cost per dose.

Discover why viral vector therapies are so expensive
Explore how manufacturers and solution providers can work together to ultimately make these drugs more cost-efficient to manufacture and ultimately reduce cost per dose
Dive into case study examples showing how the use of PI can help reduce the cost of manufacturing and ultimately cost per dose

Emmanuelle Cameau

Strategic Technology Partnership Leader, Cytiva, Genomic Medicines

Emmanuelle has more than 15 years’ experience in Biotechnology Process Development and GMP production. Highly skilled in the field of cell culture applications, Emmanuelle joined Pall Biotech (now part of Cytiva) almost 11 years ago – first as a Bioprocess Specialist (BPS). She then transitioned to the Bioreactor Applications team, where she was Principal Bioreactor Specialist for five years. She then moved to the newly formed Gene Therapy Business unit where she has been Strategic Technology Partnership Leader for the past 1.5 years+. Previously, Emmanuelle worked as Biotech Process Sciences Upstream Process development engineer at Merck Serono. She received her Biotechnology Engineer diploma from the former Ecole Supérieure d’Ingénieurs de Luminy (now Polytech Marseille). Emmanuelle is a keen horse rider and enjoys spending time with her husband and two daughters.